Sanofi Return on Investment 2010-2024 | SNY

Current and historical return on investment (ROI) values for Sanofi (SNY) over the last 10 years.
Sanofi ROI - Return on Investment Historical Data
Date TTM Net Income LT Investments & Debt Return on Investment
2024-03-31 $8.45B 17.69%
2023-12-31 $9.59B $96.00B 20.08%
2023-09-30 $10.30B 21.70%
2023-06-30 $11.11B $95.07B 23.40%
2023-03-31 $10.71B 22.82%
2022-12-31 $10.72B $94.83B 22.85%
2022-09-30 $12.21B 52.62%
2022-03-31 $8.80B 35.93%
2021-09-30 $9.03B 36.89%
2021-03-31 $10.31B inf%
2020-09-30 $9.32B inf%
2020-03-31 $7.94B inf%
2019-09-30 $6.79B 33.11%
2019-03-31 $6.71B 32.71%
2018-03-31 $6.77B 16.67%
2017-12-31 $7.07B $82.04B 17.42%
2017-09-30 $7.72B 18.98%
2017-06-30 $8.01B $80.29B 19.69%
2017-03-31 $8.14B 20.27%
2016-12-31 $7.59B $82.49B 18.91%
2016-09-30 $8.06B 41.24%
2016-06-30 $7.47B $78.17B 19.54%
2016-03-31 $7.72B 19.35%
2015-09-30 $7.96B 12.90%
2015-06-30 $7.84B $74.72B 9.42%
2014-06-30 $8.29B $84.89B 12.86%
2013-06-30 $8.36B $87.34B 12.43%
2012-06-30 $9.00B $85.62B 19.82%
2012-03-31 $8.41B 17.63%
2011-12-31 $8.89B $95.95B 18.64%
2011-09-30 $8.20B 18.80%
2011-06-30 $8.97B $94.81B 20.57%
2011-03-31 $10.32B 26.49%
2010-12-31 $9.22B $79.65B 23.67%
2010-09-30 $8.91B 23.46%
2010-06-30 $8.83B $76.10B 23.25%
2010-03-31 $8.80B 24.05%
2009-12-31 $8.81B $75.88B 24.08%
Sector Industry Market Cap Revenue
Medical Large Cap Pharmaceutical $119.456B $46.611B
Sanofi-Aventis manufactures & markets prescription drugs across countries. It focuses on major therapeutic areas such as multiple sclerosis, cardiovascular, immunology, neurology, oncology, rare blood disorders & diabetes, etc. By taking Genzyme Corporation as a subsidiary, it added products like Cerezyme, Myozyme/Lumizyme & Fabrazyme to its portfolio. Sanofi has become a major player in the CHC sector. It acquired many companies i.e. Ablynx & Bioverativ, Synthorx & Principia & Translate Bio and Kadmon. It has collaborated with companies like Regeneron among others. It develops and markets Dupixent, Kevzara & Libtayo in collaboration with Regeneron. Sanofi, along with Regeneron, is now solely responsible for Praluent marketing in & outside the U.S. Sanofi operates through 3 Global Business Units: Specialty Care (neurology & immunology, rare diseases, rare blood disorders & oncology), Vaccines & General Medicines (diabetes, cardiovascular & established products) and Consumer Healthcare, a standalone unit.
Stock Name Country Market Cap PE Ratio
Eli Lilly (LLY) United States $847.248B 122.45
Novo Nordisk (NVO) Denmark $631.845B 48.55
Johnson & Johnson (JNJ) United States $350.533B 13.92
Merck (MRK) United States $324.174B 58.98
AbbVie (ABBV) United States $302.599B 15.64
AstraZeneca (AZN) United Kingdom $243.139B 21.14
Novartis AG (NVS) Switzerland $214.497B 15.21
Pfizer (PFE) United States $155.321B 19.30
Innoviva (INVA) United States $1.013B 7.11